Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Membrane-associated RING-CH-type finger protein 9 (MARCH9) is an E3 ubiquitin ligase that plays a crucial role in the regulation of immune responses through its action on membrane proteins. It catalyzes the transfer of ubiquitin from E2 ubiquitin-conjugating enzymes to substrate proteins, particularly immune-related surface molecules such as major histocompatibility complex class I (MHC I), targeting them for endocytosis and lysosomal degradation. This downregulation of MHC I on antigen-presenting cells affects the ability of the immune system to recognize and respond to infected or malignant cells. The MARCH family of proteins, including MARCH9, are structurally homologous to viral immunosuppressive ligases and are emerging as important regulators and potential therapeutic targets in immunity, infection, and cancer[1][2][3].
Ubiquitination of surface proteins (such as MHC I), leading to their internalization and degradation in the lysosome
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Membrane-associated RING-CH-type finger protein 9 (MARCH9).